Tags

Type your tag names separated by a space and hit enter

Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study.
Neurology. 2010 Oct 19; 75(16):1408-14.Neur

Abstract

OBJECTIVE

To examine the relation between serum levels of homocysteine (tHcy) and holotranscobalamin (holoTC), the active fraction of vitamin B12, and risk of incident Alzheimer disease (AD) in a sample of Finnish community-dwelling elderly.

METHODS

A dementia-free sample of 271 subjects aged 65-79 years derived from the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study was followed up for 7 years to detect incident AD. The association between serum tHcy and holoTC with AD was analyzed with multiple logistic regression after adjusting for several potential confounders, including common vascular risk factors.

RESULTS

The odds ratios (ORs) (95% confidence interval [CI]) for AD were 1.16 (1.04-1.31) per increase of 1 μmol/L of tHcy at baseline and 0.980 (0.965-0.995) for each increase of 1 pmol/L baseline holoTC. Adjustment for several potential confounders including age, sex, education, APOE ε4 allele, body mass index, Mini-Mental State Examination, smoking, stroke, and blood pressure did not alter the associations: ORs (95% CI) for AD became 1.19 (1.01-1.39) for tHcy and 0.977 (0.958-0.997) for holoTC. Adjusting for holoTC attenuated the tHcy-AD link (OR changed from 1.16 to 1.10, 95% CI 0.96-1.25). The holoTC-AD relationship was less influenced by controlling for tHcy (OR changed from 0.980 to 0.984, 95% CI 0.968-1.000). Addition of folate did not change any of the results.

CONCLUSIONS

This study suggests that both tHcy and holoTC may be involved in the development of AD. The tHcy-AD link may be partly explained by serum holoTC. The role of holoTC in AD should be further investigated.

Authors+Show Affiliations

Aging Research Center, Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Gävlegatan 16, S 113 30, Stockholm, Sweden. babak.hooshmand@ki.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20956786

Citation

Hooshmand, B, et al. "Homocysteine and Holotranscobalamin and the Risk of Alzheimer Disease: a Longitudinal Study." Neurology, vol. 75, no. 16, 2010, pp. 1408-14.
Hooshmand B, Solomon A, Kåreholt I, et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology. 2010;75(16):1408-14.
Hooshmand, B., Solomon, A., Kåreholt, I., Leiviskä, J., Rusanen, M., Ahtiluoto, S., Winblad, B., Laatikainen, T., Soininen, H., & Kivipelto, M. (2010). Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology, 75(16), 1408-14. https://doi.org/10.1212/WNL.0b013e3181f88162
Hooshmand B, et al. Homocysteine and Holotranscobalamin and the Risk of Alzheimer Disease: a Longitudinal Study. Neurology. 2010 Oct 19;75(16):1408-14. PubMed PMID: 20956786.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. AU - Hooshmand,B, AU - Solomon,A, AU - Kåreholt,I, AU - Leiviskä,J, AU - Rusanen,M, AU - Ahtiluoto,S, AU - Winblad,B, AU - Laatikainen,T, AU - Soininen,H, AU - Kivipelto,M, PY - 2010/10/20/entrez PY - 2010/10/20/pubmed PY - 2010/11/9/medline SP - 1408 EP - 14 JF - Neurology JO - Neurology VL - 75 IS - 16 N2 - OBJECTIVE: To examine the relation between serum levels of homocysteine (tHcy) and holotranscobalamin (holoTC), the active fraction of vitamin B12, and risk of incident Alzheimer disease (AD) in a sample of Finnish community-dwelling elderly. METHODS: A dementia-free sample of 271 subjects aged 65-79 years derived from the Cardiovascular Risk Factors, Aging, and Dementia (CAIDE) study was followed up for 7 years to detect incident AD. The association between serum tHcy and holoTC with AD was analyzed with multiple logistic regression after adjusting for several potential confounders, including common vascular risk factors. RESULTS: The odds ratios (ORs) (95% confidence interval [CI]) for AD were 1.16 (1.04-1.31) per increase of 1 μmol/L of tHcy at baseline and 0.980 (0.965-0.995) for each increase of 1 pmol/L baseline holoTC. Adjustment for several potential confounders including age, sex, education, APOE ε4 allele, body mass index, Mini-Mental State Examination, smoking, stroke, and blood pressure did not alter the associations: ORs (95% CI) for AD became 1.19 (1.01-1.39) for tHcy and 0.977 (0.958-0.997) for holoTC. Adjusting for holoTC attenuated the tHcy-AD link (OR changed from 1.16 to 1.10, 95% CI 0.96-1.25). The holoTC-AD relationship was less influenced by controlling for tHcy (OR changed from 0.980 to 0.984, 95% CI 0.968-1.000). Addition of folate did not change any of the results. CONCLUSIONS: This study suggests that both tHcy and holoTC may be involved in the development of AD. The tHcy-AD link may be partly explained by serum holoTC. The role of holoTC in AD should be further investigated. SN - 1526-632X UR - https://www.unboundmedicine.com/medline/citation/20956786/Homocysteine_and_holotranscobalamin_and_the_risk_of_Alzheimer_disease:_a_longitudinal_study_ L2 - http://www.neurology.org/cgi/pmidlookup?view=long&pmid=20956786 DB - PRIME DP - Unbound Medicine ER -